Exforge HCT

RSS

amlodipine besilate / valsartan / hydrochlorothiazide

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Exforge HCT. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.

This EPAR was last updated on 07/07/2021

Authorisation details

Product details
Name
Exforge HCT
Agency product number
EMEA/H/C/001068
Active substance
  • valsartan
  • hydrochlorothiazide
  • Amlodipine besilate
International non-proprietary name (INN) or common name
  • amlodipine besilate
  • valsartan
  • hydrochlorothiazide
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09DX01
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
15/10/2009
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4
Ireland

Product information

17/06/2021 Exforge HCT - EMEA/H/C/001068 - IG/1383/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating